Surgical Management of the Axilla in Patients Presenting with Clinically Node Positive Hormone Receptor Positive, HER2 Negative (HR+/HER2-) Breast Cancer

被引：0
|
作者：
Jasper, Jacob [1 ]
Kantor, Olga [2 ]
Dorninici, Laura [3 ]
Nakhlis, Faina [4 ]
Ogayo, Esther [5 ]
Nimbkar, Suniti [6 ]
Kurt, Busem Binbogct [5 ]
King, Tari [7 ]
Mittendorf, Elizabeth [7 ]
机构：
[1] Tufts Univ, Medford, MA USA
[2] Brigham & Womens Hosp, Boston, MA USA
[3] Brigham & Womens Faulkner Hosp, Dana Farber Canc Inst, Boston, MA USA
[4] Brigham & Womens Hosp, Boston, MA USA
[5] Dana Farber Canc Inst, Boston, MA USA
[6] Dana Farber Brigham Canc Ctr, South Shore Hosp clin, Boston, MA USA
[7] Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2024年 / 31卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E44
引用
收藏
页码：S101 / S101
页数：1
相关论文
共 50 条
  • [41] The clinical impact of NOLUS in unresectable/metastatic hormone receptor-positive (HR+)/HER2-negative breast cancer
    Tajiri, Wakako
    Nakamura, Yoshiaki
    Kawasaki, Junji
    Koi, Yumiko
    Akiyoshi, Sayuri
    Koga, Chinami
    Tokunaga, Eriko
    CANCER RESEARCH, 2024, 84 (09)
  • [42] Final results of NeoMONARCH: A phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC)
    Martin, Miguel
    Hurvitz, Sara A.
    Chan, David
    Fernandez-Abad, Maria
    Petru, Edgar
    Rostorfer, Regan
    Guarneri, Valentina
    Huang, Chiun-Sheng
    Press, Michael F.
    Costigan, Timothy M.
    Caldwell, Charles W.
    Wijayawardana, Sameera
    Turner, P. Kellie
    Barriga, Susana
    Slamon, Dennis J.
    CANCER RESEARCH, 2018, 78 (04)
  • [43] A phase 1/2 dose escalation and expansion study of OP-1250 in adults with advanced and/or metastatic hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer
    Alemany, Carlos
    Patel, Manish
    Mitri, Zahi
    Sparano, Joseph
    Borges, Virginia
    Makower, Della
    Klein, Pam
    Lawrence, Julia
    Le, Trinh
    Zujewski, Jo Anne
    Harmilton, Erika
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [44] Axillary Response to Neoadjuvant Therapy in Node-Positive, Estrogen Receptor Positive, HER2 Negative Breast Cancer Patients
    Friedman-Eldar, O.
    Ozmen, T.
    Reyes, F. Valle
    Goel, N.
    Tjendra, Y.
    Moller, M.
    Kesmodel, S. B.
    Franceschi, D.
    Avisar, E.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S68 - S68
  • [45] Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
    Laidi, Fatna
    Bouziane, Amal
    Lakhdar, Amina
    Khabouze, Samira
    Rhrab, Brahim
    Zaoui, Fatima
    ONCOTARGETS AND THERAPY, 2014, 7 : 1285 - 1289
  • [46] Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)
    Laguna, J. C.
    Braso-Maristany, F.
    Pascual, T.
    Rodriguez Hernandez, A.
    Chic, N.
    Schettini, F.
    Sanfeliu Torres, E.
    Gonzalez-Farre, B.
    Martinez, D.
    Galvan, P.
    Diez-Guardia, V.
    Adamo, B.
    Vidal, M.
    Guillen Sacoto, M. C.
    Moreno, R.
    Prat, A.
    Munoz, M.
    Martinez-Saez, O.
    ANNALS OF ONCOLOGY, 2021, 32 : S69 - S70
  • [47] Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape
    Redfern, Andrew
    Burslem, Katie
    Woodward, Natasha
    Beith, Jane
    Mccarthy, Nicole
    De Boer, Richard
    Bell, Richard
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 19 - 31
  • [48] Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer
    Fedele, Palma
    Orlando, Laura
    Schiavone, Paola
    Calvani, Nicola
    Caliolo, Chiara
    Quaranta, Annamaria
    Nacci, Angelo
    Cinieri, Saverio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 94 (03) : 291 - 301
  • [49] Identification of a metabolic and canonical biomarker signature in Mexican HR+/HER2-, triple positive and triple-negative breast cancer patients
    Cecilia Pacheco-Velazquez, Silvia
    Carlos Gallardo-Perez, Juan
    Luis Aguilar-Ponce, Jose
    Villarreal, Patricia
    Ruiz-Godoy, Luz
    Perez-Sanchez, Manuel
    Marin-Hernandez, Alvaro
    Ruiz-Garcia, Erika
    Meneses-Garcia, Abelardo
    Moreno-Sanchez, Rafael
    Rodriguez-Enriquez, Sara
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (06) : 2549 - 2559
  • [50] Serum thymidine kinase activity as a "real-time" clinical biomarker of tumor response to CDK4/6 inhibition in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer
    Bagegni, Nusayba
    Williams, Amy
    Grigsby, Isabella
    Bergqvist, Mattias
    Clifton, Katherine
    Ma, Cynthia
    CANCER RESEARCH, 2024, 84 (09)
12345